Evaluation of Transmural Healing and Disease-Modifying Effects of Guselkumab in Patients with Crohn's Disease: A Phase 3b, Open-Label, Multicenter Study

The primary objective of this Phase 3b, open-label, multicenter study is to evaluate the **efficacy** of **guselkumab** in achieving **transmural healing** in patients with **Crohn's Disease**. This is assessed using the Magnetic Resonance Index of Activity (MaRIA) at Week 48. Transmural healing is a critical endpoint in Crohn's Disease management, as it indicates a deeper level of intestinal healing beyond mucosal improvement, potentially leading to better long-term outcomes and reduced disease complications.

The clinical trial involves a total of **35 participants** diagnosed with **Crohn's Disease**. The study population includes both male and female subjects, with an age range that encompasses adults and adolescents. Participants were selected based on specific criteria, including having luminal Crohn's disease for at least three months, with clinically active disease as indicated by a baseline Crohn's Disease Activity Index (CDAI) score between 220 and 450. The trial does not involve a vulnerable population. Participants are required to have active transmural activity in at least one segment, as determined by a segmental magnetic resonance index of activity (MaRIA) score of 11 or higher. Additionally, individuals must have demonstrated an inadequate response or intolerance to conventional therapy or advanced therapies. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The selection process ensures that the participants meet the necessary health criteria to evaluate the efficacy of guselkumab in achieving transmural healing at Week 48.

The clinical trial is a **Phase 3b**, open-label, multicenter study designed to evaluate the efficacy of **guselkumab** in achieving transmural healing in patients with **Crohn's disease**. The primary objective is to assess the proportion of participants achieving a Magnetic Resonance Index of Activity (MaRIA) score of less than 11 in all intestinal segments at Week 48. The trial is expected to commence recruitment on January 9, 2025, and conclude by March 26, 2028. Participants will be administered **guselkumab** either as a solution for infusion or injection, with the treatment period extending up to 80 weeks depending on the formulation used.

The trial design includes an initial screening visit to confirm eligibility based on specific inclusion criteria, such as having luminal Crohn's disease for at least three months and active transmural activity in at least one segment. Participants must also demonstrate inadequate response or intolerance to conventional therapy. Exclusion criteria are not specified in the provided data. Following the screening, eligible participants will undergo regular follow-up visits to monitor treatment efficacy and safety, with the primary endpoint assessed at Week 48. The end-of-study visit will occur at the conclusion of the treatment period, where final assessments will be conducted.

Participant involvement is expected to last for the duration of the treatment period, which may vary depending on the specific formulation of **guselkumab** administered. Conditions that may lead to early termination from the study include adverse reactions to the treatment or failure to adhere to the study protocol. The trial is not categorized as low intervention, and it is conducted under controlled conditions to ensure the reliability and validity of the results. The study aims to provide valuable insights into the disease-modifying effects of **guselkumab** in the management of **Crohn's disease**.

The clinical trial involves the administration of **Guselkumab** in various pharmaceutical forms to evaluate its efficacy in achieving transmural healing in patients with **Crohn's Disease**. The first experimental medication is **Guselkumab** in the form of a **solution for infusion** with a concentration of 10 mg/mL. This formulation is administered intravenously. The maximum treatment period for this formulation is 8 weeks. The solution is manufactured by Janssen-Cilag International N.V., and the active substance is derived from a protein of other origin.

Another formulation of **Guselkumab** used in the trial is a **solution for injection in a pre-filled syringe**. This formulation is administered subcutaneously using a Ypsomate Autoinjector PFS-Y, which is a 2 mL autoinjector device housing a pre-filled syringe with a permanently bonded ½" long needle. The maximum treatment period for this formulation is 80 weeks. The active substance remains the same, and the product is also manufactured by Janssen-Cilag International N.V.

The third formulation of **Guselkumab** is a **solution for injection in a pre-filled syringe** with a concentration of 100 mg/mL. This formulation is also administered subcutaneously, facilitated by the UltraSafe Plus™ Passive Needle Guard, which is assembled to a pre-filled syringe and enables passive activation of a needle guard after delivery. The maximum treatment period for this formulation is 72 weeks. The active substance is consistent across all formulations, and the product is manufactured by Janssen-Cilag International N.V.

Throughout the trial, participant compliance with the dosing schedules is monitored, ensuring adherence to the specified administration routes and frequencies. No non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatments, are mentioned in the trial data provided.

The efficacy of **guselkumab** in the treatment of Crohn's disease will be assessed in a Phase 3b, open-label, multicenter clinical trial. The primary endpoint for evaluating efficacy is the proportion of participants achieving a Magnetic Resonance Index of Activity (MaRIA) score of less than 11 in all intestinal segments at Week 48. This endpoint is designed to measure the transmural healing effect of the treatment.

The MaRIA score is a validated tool used to assess disease activity in Crohn's disease through magnetic resonance imaging (MRI). The trial will focus on participants with luminal Crohn's disease of at least three months' duration, who exhibit clinically active disease and have demonstrated inadequate response or intolerance to conventional or advanced therapies. The efficacy assessments will be conducted at the specified timepoint of Week 48, ensuring a comprehensive evaluation of the treatment's impact on disease activity.